Document is current
Any future updates will be listed below
-
Authors
Porsteinsson, Anton P.
Chumki, Sanjeda R. https://orcid.org/0000-0002-5882-0920
Wang, David
Such, Pedro
Palma, Anton M.
Zhang, Zhen
Shah, Alpesh
Kalu, Uwa
Montano, C. Brendan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01862640 at ClinicalTrials.govnct01922258 at ClinicalTrials.govDocuments that mention this clinical trial
Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events
https://doi.org/10.1007/s40264-026-01670-w
nct03548584 at ClinicalTrials.govDocuments that mention this clinical trial
Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events
https://doi.org/10.1007/s40264-026-01670-w
nct03594123 at ClinicalTrials.govDocuments that mention this clinical trial
Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events
https://doi.org/10.1007/s40264-026-01670-w
Documents that mention this clinical trial
Short-Term and Long-Term Safety Analyses of Brexpiprazole for Agitation Associated with Dementia due to Alzheimer’s Disease: Timing and Duration of Adverse Events
https://doi.org/10.1007/s40264-026-01670-w
-
Funding
Funding for this research was provided by:
Otsuka Pharmaceutical Development and Commercialization
H. Lundbeck A/S
- License Information
-
More Information
Article History
Received: 8 September 2025
Accepted: 16 March 2026
First Online: 10 April 2026
Declarations
:
: APP has received personal fees from Acadia Pharmaceuticals, Athira, Axsome, Biogen, BMS, Cognitive Research Corp, Cognition Therapeutics, Eisai, IQVIA, Lundbeck, MapLight Therapeutics, Novartis, Novo Nordisk, Oligomerix, ONO Pharmaceuticals, Otsuka, WCG, WebMD, and Xenon; and his institution has received grants from Athira, Biogen, Cassava, Eisai, Eli Lilly, Genentech/Roche, Vaccinex, NIA, NIMH, and DOD. He is a member of the Scientific Advisory Board of Alzheon, Athira, Cognition Therapeutics, and Oligomerix. SRC, AMP, ZZ, and AS are full-time employees of Otsuka Pharmaceutical Development & Commercialization Inc. DW and UK are full-time employees of Lundbeck LLC. PS is a full-time employee of H. Lundbeck A/S. CBM has received consulting fees from AbbVie, Acadia Pharmaceuticals, Alkermes, Arbor, Eisai, Neos, Novo Nordisk, Otsuka, Sunovion, Supernus, and Takeda, and has received payment/honoraria from AbbVie, Arbor, Eisai, Otsuka, and Takeda.
: Not applicable (post hoc analysis).
: Not applicable (post hoc analysis).
: Not applicable.
: To submit inquiries related to Otsuka clinical research, or to request access to individual participant data (IPD) associated with any Otsuka clinical trial, please visit . For all approved IPD access requests, Otsuka will share anonymized IPD on a remotely accessible data sharing platform.
: Not applicable.
: APP: Conceptualization; methodology; writing – review and editing. SRC: Conceptualization; methodology; supervision; writing – review and editing. DW: Conceptualization; methodology; supervision; writing – review and editing. PS: Conceptualization; methodology; supervision; writing – review and editing. AMP: Conceptualization; data curation; formal analysis; investigation; methodology; software; validation; visualization; writing – review and editing. ZZ: Conceptualization; data curation; formal analysis; investigation; methodology; software; validation; visualization; writing – review and editing. AS: Methodology; Writing – review and editing. UK: Methodology; writing – review and editing. CBM: Conceptualization; methodology; writing – review and editing. All authors read and approved the final version.
